Nanobiotix (NASDAQ:NBTX) — Stock Price
Nanobiotix (NASDAQ:NBTX) is currently trading at $36.18 USD, down 5.34% today. Over the past 52 weeks, shares have ranged between $7.40 and $55.07. This page tracks Nanobiotix's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NBTX market cap overview.
Nanobiotix (NBTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Nanobiotix's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Nanobiotix Income Statement — Revenue, Profit & Earnings by Year
Nanobiotix's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $29.64 Million | $-7.19 Million | $36.21 Million | $4.78 Million | $2.65 Million |
| Cost of Revenue | — | — | — | $985.00K | — |
| Gross Profit | $29.64 Million | $-7.19 Million | $36.21 Million | $4.78 Million | $2.65 Million |
| Research & Development | $23.11 Million | $40.54 Million | $38.40 Million | $32.64 Million | $30.38 Million |
| SG&A | $20.22 Million | $20.06 Million | $21.66 Million | $17.48 Million | $19.43 Million |
| Total Operating Expenses | $40.46 Million | $61.20 Million | $62.99 Million | $51.48 Million | $55.23 Million |
| Operating Income | $-10.82 Million | $-68.39 Million | $-26.78 Million | $-46.70 Million | $-52.58 Million |
| EBITDA | $-12.07 Million | $-67.67 Million | $-23.69 Million | $-44.22 Million | $-45.60 Million |
| EBIT | $-13.56 Million | $-68.26 Million | $-24.24 Million | $-45.72 Million | $-47.16 Million |
| Interest Expense | $10.39 Million | $8.09 Million | $7.98 Million | $5.84 Million | $699.49K |
| Income Before Tax | $-23.96 Million | $-68.03 Million | $-39.58 Million | $-57.03 Million | $-47.00 Million |
| Income Tax Expense | $3.00K | $101.00K | $120.00K | $10.00K | $5.00K |
| Net Income | $-23.96 Million | $-68.13 Million | $-39.70 Million | $-57.04 Million | $-47.00 Million |
Nanobiotix Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Nanobiotix's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $67.76 Million | $67.42 Million | $93.90 Million | $59.77 Million | $101.77 Million |
| Total Current Assets | $62.75 Million | $61.47 Million | $87.34 Million | $52.36 Million | $93.06 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | $2.81 Million | — |
| Net Receivables | $7.68 Million | $8.54 Million | $2.97 Million | $2.84 Million | $3.89 Million |
| Inventory | — | — | $200.00K | $2.98 Million | $-3.04 Million |
| Property, Plant & Equipment | — | — | — | $7.12 Million | $8.19 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $152.24 Million | $133.12 Million | $95.74 Million | $86.81 Million | $74.98 Million |
| Total Current Liabilities | $57.51 Million | $58.94 Million | $49.87 Million | $37.94 Million | $36.84 Million |
| Long-term Debt | $89.12 Million | $43.01 Million | $41.66 Million | $44.04 Million | $32.42 Million |
| Net Debt | $42.57 Million | $1.17 Million | $-24.72 Million | $11.78 Million | $-37.90 Million |
| Total Stockholder Equity | $-84.48 Million | $-65.70 Million | $-1.84 Million | $-27.05 Million | $26.79 Million |
| Retained Earnings | $-23.96 Million | $-68.13 Million | $-39.70 Million | $-57.04 Million | $-47.00 Million |
Nanobiotix Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Nanobiotix generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-33.42 Million | $-19.55 Million | $-12.48 Million | $-37.10 Million | $-29.87 Million |
| Capital Expenditures | $546.00K | $846.00K | $328.00K | $92.00K | $228.00K |
| Free Cash Flow | $-33.97 Million | $-20.40 Million | $-12.80 Million | $-37.20 Million | $-30.10 Million |
| Investing Cash Flow | $-578.00K | $-955.00K | $-349.00K | $138.00K | $-242.00K |
| Financing Cash Flow | $37.42 Million | $-5.13 Million | $46.77 Million | $-5.65 Million | $-5.18 Million |
| Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-Based Compensation | $3.54 Million | $4.30 Million | $3.30 Million | $3.17 Million | $3.20 Million |
| Depreciation | $1.50 Million | $1.62 Million | $1.51 Million | $1.50 Million | $1.56 Million |
| Change in Cash | $3.01 Million | $-25.55 Million | $33.90 Million | $-42.53 Million | $-35.23 Million |
Nanobiotix Earnings History — EPS Actual vs. Analyst Estimates
Track Nanobiotix's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 28, 2026 | 0.00 | -0.39 | +100.00% |
| Nov 28, 2025 | 0.00 | 0.00 | — |
| Sep 24, 2025 | -0.13 | -0.35 | +63.84% |
| Apr 02, 2025 | -0.98 | -0.73 | -33.86% |
| Nov 29, 2024 | 0.00 | 0.00 | — |
| Sep 18, 2024 | -0.50 | -0.51 | +1.90% |
| Apr 24, 2024 | -0.13 | -0.13 | +1.08% |
| Nov 13, 2023 | 0.00 | 0.00 | — |